Gilead­'s twice-a-year in­jec­tion ful­ly pre­vent­ed HIV in Phase 3 study with cis­gen­der women

There were no cas­es of HIV in over 2,000 cis­gen­der women who re­ceived a twice-a-year pre­ven­tive HIV in­jec­tion de­vel­oped by Gilead as part of a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.